Cargando…

Risk interrelationship among multiple primary tumors: A case report and review of literature

RATIONALE: Along with advanced management in oncology, great progress has been recently achieved in the studies of multiple primary tumors. Several reports have studied the coexistence between lymphoma and either renal cell carcinoma (RCC) or Warthin tumor. However, the level of coexistence between...

Descripción completa

Detalles Bibliográficos
Autores principales: Safi, Mohammed, Sun, Xiuhua, Wang, Lifen, Zhang, Xinwei, Song, Jicheng, Ameen, Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908637/
https://www.ncbi.nlm.nih.gov/pubmed/29642151
http://dx.doi.org/10.1097/MD.0000000000010289
_version_ 1783315750791938048
author Safi, Mohammed
Sun, Xiuhua
Wang, Lifen
Zhang, Xinwei
Song, Jicheng
Ameen, Mohammed
author_facet Safi, Mohammed
Sun, Xiuhua
Wang, Lifen
Zhang, Xinwei
Song, Jicheng
Ameen, Mohammed
author_sort Safi, Mohammed
collection PubMed
description RATIONALE: Along with advanced management in oncology, great progress has been recently achieved in the studies of multiple primary tumors. Several reports have studied the coexistence between lymphoma and either renal cell carcinoma (RCC) or Warthin tumor. However, the level of coexistence between these cases remains unclear due to the absence of a distinct link between them. PATIENT CONCERNS: We present a unique case of multiple primary tumors (lymphoma, RCC, and Warthin tumor) in an 80-year-old man and a review of the literature on the coexistence of RCC with lymphoma and lymphoma with Warthin tumor. DIAGNOSIS: With a history of RCC, the patient had a freely movable lump under his left ear, and the pathological report indicated Hodgkin lymphoma and Warthin tumor. INTERVENTION: RCC and Warthin tumor of the patient were surgically treated, followed by 2 cycles (14 days per cycle) of Epirubicin 40 mg day 1, Bleomycin 8 mg day 1, Vincristine 2 mg day 1, and Dacarbazine 500 mg day 1. The chemotherapy protocol was then changed to Epirubicin 40 mg day 1, Vincristine 2 mg day 1, and Dacarbazine 500 mg day 1 for 7 cycles. OUTCOMES: After the last day of chemotherapy, the patient showed a complete response. LESSONS: To the best of our knowledge, this paper is the first to report a case of multiple primary tumors with a complete response. For their early detection, favorable prognosis, and correlation identification, we suggest a transitive relation between these coexisting tumors. Therefore, similar studies should be conducted.
format Online
Article
Text
id pubmed-5908637
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-59086372018-04-30 Risk interrelationship among multiple primary tumors: A case report and review of literature Safi, Mohammed Sun, Xiuhua Wang, Lifen Zhang, Xinwei Song, Jicheng Ameen, Mohammed Medicine (Baltimore) 4100 RATIONALE: Along with advanced management in oncology, great progress has been recently achieved in the studies of multiple primary tumors. Several reports have studied the coexistence between lymphoma and either renal cell carcinoma (RCC) or Warthin tumor. However, the level of coexistence between these cases remains unclear due to the absence of a distinct link between them. PATIENT CONCERNS: We present a unique case of multiple primary tumors (lymphoma, RCC, and Warthin tumor) in an 80-year-old man and a review of the literature on the coexistence of RCC with lymphoma and lymphoma with Warthin tumor. DIAGNOSIS: With a history of RCC, the patient had a freely movable lump under his left ear, and the pathological report indicated Hodgkin lymphoma and Warthin tumor. INTERVENTION: RCC and Warthin tumor of the patient were surgically treated, followed by 2 cycles (14 days per cycle) of Epirubicin 40 mg day 1, Bleomycin 8 mg day 1, Vincristine 2 mg day 1, and Dacarbazine 500 mg day 1. The chemotherapy protocol was then changed to Epirubicin 40 mg day 1, Vincristine 2 mg day 1, and Dacarbazine 500 mg day 1 for 7 cycles. OUTCOMES: After the last day of chemotherapy, the patient showed a complete response. LESSONS: To the best of our knowledge, this paper is the first to report a case of multiple primary tumors with a complete response. For their early detection, favorable prognosis, and correlation identification, we suggest a transitive relation between these coexisting tumors. Therefore, similar studies should be conducted. Wolters Kluwer Health 2018-04-13 /pmc/articles/PMC5908637/ /pubmed/29642151 http://dx.doi.org/10.1097/MD.0000000000010289 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-nc-sa/4.0
spellingShingle 4100
Safi, Mohammed
Sun, Xiuhua
Wang, Lifen
Zhang, Xinwei
Song, Jicheng
Ameen, Mohammed
Risk interrelationship among multiple primary tumors: A case report and review of literature
title Risk interrelationship among multiple primary tumors: A case report and review of literature
title_full Risk interrelationship among multiple primary tumors: A case report and review of literature
title_fullStr Risk interrelationship among multiple primary tumors: A case report and review of literature
title_full_unstemmed Risk interrelationship among multiple primary tumors: A case report and review of literature
title_short Risk interrelationship among multiple primary tumors: A case report and review of literature
title_sort risk interrelationship among multiple primary tumors: a case report and review of literature
topic 4100
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908637/
https://www.ncbi.nlm.nih.gov/pubmed/29642151
http://dx.doi.org/10.1097/MD.0000000000010289
work_keys_str_mv AT safimohammed riskinterrelationshipamongmultipleprimarytumorsacasereportandreviewofliterature
AT sunxiuhua riskinterrelationshipamongmultipleprimarytumorsacasereportandreviewofliterature
AT wanglifen riskinterrelationshipamongmultipleprimarytumorsacasereportandreviewofliterature
AT zhangxinwei riskinterrelationshipamongmultipleprimarytumorsacasereportandreviewofliterature
AT songjicheng riskinterrelationshipamongmultipleprimarytumorsacasereportandreviewofliterature
AT ameenmohammed riskinterrelationshipamongmultipleprimarytumorsacasereportandreviewofliterature